Aurinia Pharmaceuticals Inc

Company Profile

Aurinia Pharmaceuticals Inc had its IPO on 1999-01-26 under the ticker symbol AUPH.

The company operates in the Healthcare sector and Biotechnology industry. Aurinia Pharmaceuticals Inc has a staff strength of 300 employees.

Stock update

Shares of Aurinia Pharmaceuticals Inc opened at $9.48 at the start of the last trading session i.e. 2023-03-19.

The stocks traded within a range of $9.36 - $9.78, and closed at $9.51.

This is a -0.63% slip from the previous day's closing price.

A total volume of 2,529,000 shares were traded at the close of the day’s session.

In the last one week, shares of Aurinia Pharmaceuticals Inc have slipped by -0.21%.

Aurinia Pharmaceuticals Inc's Key Ratios

Aurinia Pharmaceuticals Inc has a market cap of $1.36 billion, indicating a price to book ratio of 1.5673 and a price to sales ratio of 4.9298.

In the last 12-months Aurinia Pharmaceuticals Inc’s revenue was $134.03 million with a gross profit of $83.38 million and an EBITDA of $-108764000. The EBITDA ratio measures Aurinia Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Aurinia Pharmaceuticals Inc’s operating margin was -83.17% while its return on assets stood at -13.74% with a return of equity of -24.46%.

In Q4, Aurinia Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 21.5%.

Aurinia Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE

434.7826

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-0.77 per share while it has a forward price to earnings multiple of 434.7826 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aurinia Pharmaceuticals Inc’s profitability.

Aurinia Pharmaceuticals Inc stock is trading at a EV to sales ratio of 2.2884 and a EV to EBITDA ratio of -2.6157. Its price to sales ratio in the trailing 12-months stood at 4.9298.

Aurinia Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$470.86 million

Total Liabilities

$46.11 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Aurinia Pharmaceuticals Inc ended 2023 with $470.86 million in total assets and $0 in total liabilities. Its intangible assets were valued at $470.86 million while shareholder equity stood at $405.44 million.

Aurinia Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $46.11 million in other current liabilities, 1185309000.00 in common stock, $-864302000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $94.17 million and cash and short-term investments were $389.39 million. The company’s total short-term debt was $936,000 while long-term debt stood at $0.

Aurinia Pharmaceuticals Inc’s total current assets stands at $442.54 million while long-term investments were $0 and short-term investments were $295.22 million. Its net receivables were $13.48 million compared to accounts payable of $3.09 million and inventory worth $24.75 million.

In 2023, Aurinia Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Aurinia Pharmaceuticals Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$9.51

52-Week High

$13.415

52-Week Low

$4.07

Analyst Target Price

$13

Aurinia Pharmaceuticals Inc stock is currently trading at $9.51 per share. It touched a 52-week high of $13.415 and a 52-week low of $13.415. Analysts tracking the stock have a 12-month average target price of $13.

Its 50-day moving average was $8.64 and 200-day moving average was $7.97 The short ratio stood at 6.1 indicating a short percent outstanding of 0%.

Around 698.7% of the company’s stock are held by insiders while 3834.9% are held by institutions.